Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
1,810.30
+5.40 (0.30%)
At close: Nov 27, 2025
NSE:SUNPHARMA Revenue
Sun Pharmaceutical Industries had revenue of 144.78B INR in the quarter ending September 30, 2025, with 8.93% growth. This brings the company's revenue in the last twelve months to 549.64B, up 9.26% year-over-year. In the fiscal year ending March 31, 2025, Sun Pharmaceutical Industries had annual revenue of 525.78B with 8.42% growth.
Revenue (ttm)
549.64B
Revenue Growth
+9.26%
P/S Ratio
7.90
Revenue / Employee
12.78M
Employees
43,000
Market Cap
4.34T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 525.78B | 40.82B | 8.42% |
| Mar 31, 2024 | 484.97B | 46.11B | 10.51% |
| Mar 31, 2023 | 438.86B | 52.31B | 13.53% |
| Mar 31, 2022 | 386.54B | 51.56B | 15.39% |
| Mar 31, 2021 | 334.98B | 6.61B | 2.01% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 164.76B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
Sun Pharmaceutical Industries News
- 9 days ago - AstraZeneca Pharma India jumps 3% after teaming up with Sun Pharma to boost access to Hyperkalaemia treatment in India - Business Upturn
- 10 days ago - AstraZeneca and Sun Pharma partner to boost access to Hyperkalaemia treatment in India - Business Upturn
- 15 days ago - Why are Sun Pharma shares falling today? Explained - Business Upturn
- 15 days ago - Sun Pharma’s partner Philogen reports positive survival trends in Fibromun Phase III study for soft tissue sarcoma - Business Upturn
- 20 days ago - Sun Pharma share: Nomura upgrades to buy, expects 16% upside on strong branded generics growth and favourable risk-reward - Business Upturn
- 22 days ago - Sun Pharmaceuticals Industries Ltd (BOM:524715) Q2 2026 Earnings Call Highlights: Strong Sales ... - GuruFocus
- 22 days ago - Q2 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript - GuruFocus
- 23 days ago - Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q2 2026 Earnings Report Preview: What To Expect - GuruFocus